Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: an Analysis of the Surveillance, Epidemiology, and End Results Registry
Authors:
- Mathias WorniMWMathias Worni
- Igor AkushevichIAIgor Akushevich
- Beat GloorBGBeat Gloor
- John ScarboroughJSJohn Scarborough
- Junzo P. ChinoJCJunzo P. Chino
- Danny O. JacobsDJDanny O. Jacobs
- Stephen M. HahnSHStephen M. Hahn
- Bryan M. ClaryBCBryan M. Clary
- Ricardo PietrobonRPRicardo Pietrobon
- 15 October 2011
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 19 (4) , 1316-1323
Abstract
Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS) among patients undergoing surgical resection for invasive IPMN. The Surveillance, Epidemiology, and End Results (SEER) registry was used in this retrospective cohort study. All adult patients with resection of invasive IPMN from 1988 to 2007 were included. CSS and OS were analyzed using Kaplan-Meier curves. Unadjusted and propensity-score-adjusted Cox proportional-hazards modeling were used for subgroup analyses. 972 patients were included. Adjuvant RT was administered to 31.8% (n=309) of patients. There was no difference in overall median CSS or OS in patients who received adjuvant RT (5-year CSS: 26.5 months; 5-year OS: 23.5 months) versus those who did not (CSS: 28.5 months, P=0.17; OS: 23.5 months, P=0.23). Univariate predictors of survival were lymph node (LN) involvement, T4-classified tumors, and poorly differentiated tumor grade (all P<0.05). In the propensity-score-adjusted analysis, adjuvant RT was associated with improved 5-year CSS [hazard ratio (HR): 0.67, P=0.004] and 5-year OS (HR: 0.73, P=0.014) among all patients with LN involvement, though further analysis by T-classification demonstrated no survival differences among patients with T1/T2 disease; patients with T3/T4-classified tumors had improved CSS (HR: 0.71, P=0.022) but no difference in OS (HR: 0.76, P=0.06). On propensity-score-adjusted analysis, adjuvant RT was associated with improved survival in selected subsets of patients with invasive IPMN, particularly those with T3/T4 tumors and LN involvement.Keywords
This publication has 34 references indexed in Scilit:
- Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapyHPB, 2010
- Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the PancreasAnnals of Surgery, 2010
- Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreasWorld Journal of Gastrointestinal Surgery, 2010
- Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patientsWorld Journal of Gastrointestinal Surgery, 2010
- Outcome of Invasive and Noninvasive Intraductal Papillary‐Mucinous Neoplasms of the Pancreas (IPMN): A 10‐year ExperienceWorld Journal of Surgery, 2008
- Experience With 208 Resections for Intraductal Papillary Mucinous Neoplasm of the PancreasArchives of Surgery, 2008
- Surgical Outcome of Intraductal Papillary Mucinous Neoplasms of the PancreasAnnals of Surgical Oncology, 2007
- Incidence of Additional Primary Cancers in Patients with Invasive Intraductal Papillary Mucinous Neoplasms and Sporadic Pancreatic AdenocarcinomasJournal of the American College of Surgeons, 2007
- Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreasThe American Journal of Surgery, 2005
- Intraductal Papillary Mucinous Neoplasms of the PancreasAnnals of Surgery, 2004